Sujatha Venkataraman
Concepts (350)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioma | 13 | 2025 | 397 | 2.740 |
Why?
| | Medulloblastoma | 16 | 2023 | 196 | 2.640 |
Why?
| | Cerebellar Neoplasms | 12 | 2023 | 155 | 2.090 |
Why?
| | Gene Expression Regulation, Neoplastic | 19 | 2025 | 1402 | 1.080 |
Why?
| | Nuclear Proteins | 7 | 2025 | 710 | 1.010 |
Why?
| | Brain Neoplasms | 7 | 2025 | 1241 | 0.970 |
Why?
| | 12E7 Antigen | 1 | 2025 | 10 | 0.970 |
Why?
| | Cell Line, Tumor | 29 | 2025 | 3420 | 0.960 |
Why?
| | Superoxide Dismutase | 14 | 2016 | 346 | 0.960 |
Why?
| | Cell Proliferation | 23 | 2025 | 2482 | 0.960 |
Why?
| | Rhabdoid Tumor | 5 | 2025 | 99 | 0.960 |
Why?
| | Radiation Tolerance | 6 | 2022 | 98 | 0.880 |
Why?
| | Polycomb Repressive Complex 1 | 2 | 2020 | 51 | 0.750 |
Why?
| | Cell Cycle Proteins | 8 | 2022 | 614 | 0.680 |
Why?
| | Antineoplastic Agents | 8 | 2025 | 2145 | 0.660 |
Why?
| | Reactive Oxygen Species | 9 | 2022 | 619 | 0.650 |
Why?
| | Teratoma | 4 | 2022 | 114 | 0.620 |
Why?
| | Apoptosis | 16 | 2025 | 2557 | 0.600 |
Why?
| | Proto-Oncogene Proteins c-myc | 3 | 2021 | 141 | 0.590 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1428 | 0.580 |
Why?
| | Neoplastic Stem Cells | 3 | 2025 | 398 | 0.570 |
Why?
| | Histones | 6 | 2025 | 641 | 0.510 |
Why?
| | Central Nervous System Neoplasms | 2 | 2023 | 158 | 0.490 |
Why?
| | Ependymoma | 3 | 2025 | 168 | 0.470 |
Why?
| | Proto-Oncogene Proteins | 4 | 2022 | 646 | 0.470 |
Why?
| | Brain Stem Neoplasms | 3 | 2021 | 83 | 0.460 |
Why?
| | MicroRNAs | 2 | 2012 | 704 | 0.460 |
Why?
| | Superoxides | 5 | 2010 | 202 | 0.450 |
Why?
| | Pyrazoles | 7 | 2022 | 427 | 0.440 |
Why?
| | Tumor Cells, Cultured | 9 | 2025 | 957 | 0.420 |
Why?
| | Xenograft Model Antitumor Assays | 6 | 2025 | 868 | 0.420 |
Why?
| | Cellular Senescence | 3 | 2019 | 188 | 0.410 |
Why?
| | Protein-Tyrosine Kinases | 4 | 2020 | 434 | 0.410 |
Why?
| | Cerebellum | 3 | 2012 | 225 | 0.390 |
Why?
| | SMARCB1 Protein | 2 | 2025 | 31 | 0.380 |
Why?
| | Mice | 19 | 2025 | 17843 | 0.380 |
Why?
| | Chromatin | 4 | 2025 | 524 | 0.370 |
Why?
| | Repressor Proteins | 2 | 2012 | 425 | 0.340 |
Why?
| | Prostatic Neoplasms | 3 | 2016 | 1034 | 0.340 |
Why?
| | Intracellular Space | 1 | 2010 | 69 | 0.330 |
Why?
| | Transcription Factors | 3 | 2023 | 1717 | 0.330 |
Why?
| | Aging | 1 | 2020 | 1866 | 0.330 |
Why?
| | Pyrimidines | 5 | 2017 | 472 | 0.320 |
Why?
| | RNA, Messenger | 5 | 2014 | 2838 | 0.320 |
Why?
| | Cell Cycle | 9 | 2017 | 604 | 0.310 |
Why?
| | Cell Survival | 8 | 2017 | 1122 | 0.310 |
Why?
| | Biomarkers, Tumor | 4 | 2020 | 1279 | 0.310 |
Why?
| | Mutation | 4 | 2025 | 3964 | 0.290 |
Why?
| | Humans | 60 | 2025 | 137514 | 0.290 |
Why?
| | Animals | 21 | 2025 | 37011 | 0.290 |
Why?
| | NF-kappa B | 3 | 2025 | 694 | 0.270 |
Why?
| | Hydrogen Peroxide | 8 | 2008 | 320 | 0.260 |
Why?
| | DNA Repair | 3 | 2025 | 230 | 0.260 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 4 | 2016 | 277 | 0.240 |
Why?
| | Pyrimidinones | 4 | 2020 | 114 | 0.240 |
Why?
| | Homologous Recombination | 1 | 2025 | 26 | 0.240 |
Why?
| | Blotting, Western | 6 | 2014 | 1227 | 0.240 |
Why?
| | Sirtuin 2 | 1 | 2025 | 25 | 0.230 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2025 | 51 | 0.230 |
Why?
| | Azepines | 3 | 2019 | 90 | 0.230 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 1060 | 0.230 |
Why?
| | Protein-Arginine N-Methyltransferases | 1 | 2025 | 27 | 0.230 |
Why?
| | Infratentorial Neoplasms | 1 | 2025 | 63 | 0.230 |
Why?
| | Piperazines | 4 | 2025 | 351 | 0.230 |
Why?
| | Oligonucleotide Array Sequence Analysis | 4 | 2016 | 765 | 0.220 |
Why?
| | Positive Transcriptional Elongation Factor B | 1 | 2024 | 29 | 0.220 |
Why?
| | Radiation, Ionizing | 2 | 2022 | 81 | 0.210 |
Why?
| | Radiation | 2 | 2021 | 24 | 0.210 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2014 | 344 | 0.210 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2019 | 328 | 0.210 |
Why?
| | Epigenomics | 2 | 2020 | 115 | 0.200 |
Why?
| | Fever | 1 | 2004 | 307 | 0.200 |
Why?
| | Genes, myc | 2 | 2020 | 48 | 0.200 |
Why?
| | Cyclin-Dependent Kinase 6 | 2 | 2012 | 42 | 0.200 |
Why?
| | Phthalazines | 2 | 2025 | 45 | 0.190 |
Why?
| | Molecular Targeted Therapy | 2 | 2016 | 414 | 0.190 |
Why?
| | Killer Cells, Natural | 1 | 2025 | 446 | 0.190 |
Why?
| | von Willebrand Diseases | 1 | 2022 | 27 | 0.190 |
Why?
| | Radiation-Sensitizing Agents | 2 | 2025 | 43 | 0.190 |
Why?
| | Child | 14 | 2025 | 22037 | 0.190 |
Why?
| | von Willebrand Factor | 1 | 2022 | 81 | 0.190 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 66 | 0.180 |
Why?
| | Cell Differentiation | 5 | 2025 | 1979 | 0.180 |
Why?
| | Receptor, trkC | 1 | 2021 | 11 | 0.180 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 234 | 0.180 |
Why?
| | Single-Cell Analysis | 2 | 2022 | 309 | 0.180 |
Why?
| | Receptor, trkB | 1 | 2021 | 34 | 0.180 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2021 | 68 | 0.170 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 228 | 0.170 |
Why?
| | Mice, Nude | 3 | 2020 | 696 | 0.170 |
Why?
| | Receptor, EphB4 | 1 | 2020 | 37 | 0.170 |
Why?
| | Ephrin-B2 | 1 | 2020 | 51 | 0.170 |
Why?
| | Transcriptional Elongation Factors | 1 | 2020 | 40 | 0.160 |
Why?
| | RNA, Small Interfering | 4 | 2022 | 621 | 0.160 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2020 | 80 | 0.160 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2019 | 17 | 0.160 |
Why?
| | Free Radicals | 4 | 2009 | 109 | 0.160 |
Why?
| | Astrocytoma | 1 | 2020 | 128 | 0.160 |
Why?
| | Karyopherins | 1 | 2019 | 18 | 0.160 |
Why?
| | Catalase | 4 | 2008 | 131 | 0.160 |
Why?
| | Pteridines | 2 | 2016 | 20 | 0.150 |
Why?
| | Deoxycytidine | 1 | 2020 | 176 | 0.150 |
Why?
| | Sulfonamides | 1 | 2022 | 513 | 0.150 |
Why?
| | Membrane Glycoproteins | 1 | 2021 | 501 | 0.150 |
Why?
| | Lysine | 1 | 2020 | 297 | 0.140 |
Why?
| | Promoter Regions, Genetic | 5 | 2017 | 1255 | 0.140 |
Why?
| | Enzyme Inhibitors | 4 | 2020 | 845 | 0.140 |
Why?
| | Child, Preschool | 7 | 2021 | 11097 | 0.140 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 220 | 0.140 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 531 | 0.140 |
Why?
| | Everolimus | 1 | 2017 | 91 | 0.140 |
Why?
| | Gene Expression Profiling | 3 | 2014 | 1770 | 0.140 |
Why?
| | Recombinational DNA Repair | 1 | 2017 | 16 | 0.140 |
Why?
| | Cisplatin | 2 | 2016 | 318 | 0.130 |
Why?
| | Triazoles | 2 | 2019 | 151 | 0.130 |
Why?
| | Morpholines | 1 | 2017 | 126 | 0.130 |
Why?
| | Glioblastoma | 1 | 2020 | 344 | 0.130 |
Why?
| | Checkpoint Kinase 1 | 1 | 2016 | 30 | 0.130 |
Why?
| | Immunophenotyping | 1 | 2017 | 321 | 0.130 |
Why?
| | E1A-Associated p300 Protein | 1 | 2016 | 12 | 0.130 |
Why?
| | Cell Movement | 3 | 2020 | 972 | 0.130 |
Why?
| | Neoplasm Invasiveness | 2 | 2020 | 510 | 0.130 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2016 | 86 | 0.120 |
Why?
| | Mitochondria | 4 | 2006 | 947 | 0.120 |
Why?
| | Glutathione Peroxidase | 2 | 2006 | 43 | 0.120 |
Why?
| | Metalloporphyrins | 1 | 2016 | 103 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 437 | 0.120 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2016 | 145 | 0.120 |
Why?
| | Female | 16 | 2025 | 73162 | 0.120 |
Why?
| | Tumor Suppressor Proteins | 1 | 2017 | 328 | 0.120 |
Why?
| | Ultraviolet Rays | 2 | 2009 | 389 | 0.120 |
Why?
| | Polycomb Repressive Complex 2 | 2 | 2012 | 66 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 974 | 0.120 |
Why?
| | Up-Regulation | 3 | 2016 | 846 | 0.110 |
Why?
| | Neural Stem Cells | 2 | 2012 | 157 | 0.110 |
Why?
| | DNA Methylation | 3 | 2021 | 644 | 0.110 |
Why?
| | Survival Rate | 2 | 2020 | 1980 | 0.110 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2016 | 260 | 0.110 |
Why?
| | Signal Transduction | 5 | 2025 | 5096 | 0.110 |
Why?
| | Protein Processing, Post-Translational | 1 | 2016 | 471 | 0.100 |
Why?
| | Cathepsin B | 1 | 2012 | 14 | 0.100 |
Why?
| | Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2012 | 28 | 0.100 |
Why?
| | Argonaute Proteins | 1 | 2012 | 27 | 0.100 |
Why?
| | Prognosis | 3 | 2020 | 4031 | 0.100 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 3 | 2023 | 51 | 0.100 |
Why?
| | Aurora Kinases | 1 | 2012 | 27 | 0.100 |
Why?
| | 3' Untranslated Regions | 1 | 2012 | 145 | 0.090 |
Why?
| | Early Growth Response Protein 1 | 1 | 2011 | 27 | 0.090 |
Why?
| | Aurora Kinase A | 1 | 2012 | 56 | 0.090 |
Why?
| | Xanthine Oxidase | 1 | 2011 | 81 | 0.090 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 170 | 0.090 |
Why?
| | Dioxygenases | 1 | 2011 | 28 | 0.090 |
Why?
| | Breast | 2 | 2008 | 153 | 0.090 |
Why?
| | Cyclin D1 | 2 | 2008 | 67 | 0.090 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2017 | 620 | 0.080 |
Why?
| | CpG Islands | 1 | 2011 | 160 | 0.080 |
Why?
| | Neoplasm Grading | 2 | 2021 | 308 | 0.080 |
Why?
| | Halogenated Diphenyl Ethers | 1 | 2009 | 5 | 0.080 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2021 | 196 | 0.080 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2012 | 538 | 0.080 |
Why?
| | Male | 11 | 2021 | 67718 | 0.080 |
Why?
| | Neoplasm Proteins | 1 | 2012 | 433 | 0.080 |
Why?
| | DNA-Binding Proteins | 2 | 2016 | 1507 | 0.080 |
Why?
| | Polychlorinated Biphenyls | 1 | 2008 | 11 | 0.070 |
Why?
| | Brain | 3 | 2023 | 2831 | 0.070 |
Why?
| | Tumor Stem Cell Assay | 2 | 2006 | 34 | 0.070 |
Why?
| | Cell Hypoxia | 2 | 2008 | 227 | 0.070 |
Why?
| | Carrier Proteins | 1 | 2012 | 770 | 0.070 |
Why?
| | Quinazolines | 2 | 2022 | 249 | 0.070 |
Why?
| | Down-Regulation | 1 | 2010 | 658 | 0.070 |
Why?
| | Hypoxia | 2 | 2011 | 1108 | 0.070 |
Why?
| | Transfection | 3 | 2019 | 948 | 0.070 |
Why?
| | Dicumarol | 1 | 2006 | 3 | 0.070 |
Why?
| | DNA Copy Number Variations | 2 | 2021 | 185 | 0.070 |
Why?
| | Electron Spin Resonance Spectroscopy | 4 | 2008 | 94 | 0.060 |
Why?
| | Transcription Factor AP-2 | 1 | 2006 | 83 | 0.060 |
Why?
| | Acetylcysteine | 1 | 2007 | 147 | 0.060 |
Why?
| | G2 Phase | 1 | 2006 | 38 | 0.060 |
Why?
| | Base Sequence | 1 | 2010 | 2180 | 0.060 |
Why?
| | Energy Metabolism | 1 | 2012 | 895 | 0.060 |
Why?
| | Cells, Cultured | 5 | 2016 | 4206 | 0.060 |
Why?
| | Ubiquitination | 1 | 2025 | 104 | 0.060 |
Why?
| | Transcriptome | 2 | 2022 | 974 | 0.060 |
Why?
| | Mouth Neoplasms | 1 | 2006 | 120 | 0.060 |
Why?
| | Keratinocytes | 1 | 2006 | 248 | 0.060 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2025 | 43 | 0.060 |
Why?
| | Epithelial Cells | 2 | 2008 | 1099 | 0.060 |
Why?
| | Aconitate Hydratase | 1 | 2004 | 17 | 0.060 |
Why?
| | Oxygen | 2 | 2012 | 943 | 0.060 |
Why?
| | Hypertension, Pulmonary | 1 | 2016 | 1903 | 0.060 |
Why?
| | Phosphorylation | 2 | 2020 | 1762 | 0.060 |
Why?
| | Lipid Peroxidation | 1 | 2004 | 152 | 0.060 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2004 | 98 | 0.050 |
Why?
| | Phenotype | 1 | 2012 | 3205 | 0.050 |
Why?
| | DNA Damage | 2 | 2017 | 420 | 0.050 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2025 | 117 | 0.050 |
Why?
| | Epigenesis, Genetic | 2 | 2020 | 660 | 0.050 |
Why?
| | Membrane Potentials | 1 | 2004 | 294 | 0.050 |
Why?
| | Androgens | 1 | 2005 | 188 | 0.050 |
Why?
| | Carcinogenesis | 1 | 2025 | 220 | 0.050 |
Why?
| | Tyrosine | 1 | 2023 | 224 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2005 | 544 | 0.050 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2023 | 171 | 0.050 |
Why?
| | Weibel-Palade Bodies | 1 | 2022 | 6 | 0.050 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 45 | 0.050 |
Why?
| | Spheroids, Cellular | 2 | 2012 | 76 | 0.050 |
Why?
| | Gene Ontology | 1 | 2021 | 53 | 0.050 |
Why?
| | Hot Temperature | 1 | 2004 | 409 | 0.050 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2022 | 104 | 0.050 |
Why?
| | Transcriptional Activation | 2 | 2017 | 379 | 0.040 |
Why?
| | RNA Polymerase II | 1 | 2024 | 324 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2066 | 0.040 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2006 | 683 | 0.040 |
Why?
| | Macrophages, Alveolar | 1 | 2004 | 392 | 0.040 |
Why?
| | Oxidation-Reduction | 3 | 2011 | 1059 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2023 | 455 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2022 | 197 | 0.040 |
Why?
| | Oxidative Stress | 4 | 2011 | 1307 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2021 | 305 | 0.040 |
Why?
| | Time Factors | 3 | 2006 | 6817 | 0.040 |
Why?
| | Biopsy | 1 | 2023 | 1132 | 0.040 |
Why?
| | Immunotherapy, Adoptive | 1 | 2023 | 324 | 0.040 |
Why?
| | Kinetics | 3 | 2008 | 1679 | 0.040 |
Why?
| | Airway Resistance | 1 | 1999 | 36 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2023 | 720 | 0.040 |
Why?
| | Cell Self Renewal | 1 | 2019 | 54 | 0.040 |
Why?
| | RNA Interference | 2 | 2012 | 464 | 0.040 |
Why?
| | Pancreatic Neoplasms | 1 | 2006 | 943 | 0.040 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2019 | 135 | 0.040 |
Why?
| | Pneumonia | 1 | 2004 | 638 | 0.040 |
Why?
| | Transcription, Genetic | 1 | 2024 | 1458 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 62 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 682 | 0.030 |
Why?
| | Fibroblasts | 3 | 2008 | 990 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 125 | 0.030 |
Why?
| | Computer Simulation | 1 | 2021 | 986 | 0.030 |
Why?
| | Cohort Studies | 2 | 2021 | 5730 | 0.030 |
Why?
| | Breast Neoplasms | 3 | 2006 | 2249 | 0.030 |
Why?
| | Benzamides | 1 | 2017 | 218 | 0.030 |
Why?
| | Benzodiazepinones | 1 | 2016 | 17 | 0.030 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2016 | 24 | 0.030 |
Why?
| | Enzyme Repression | 1 | 2016 | 6 | 0.030 |
Why?
| | Urea | 1 | 2016 | 81 | 0.030 |
Why?
| | Radiation-Protective Agents | 1 | 2016 | 26 | 0.030 |
Why?
| | Thiophenes | 1 | 2016 | 118 | 0.030 |
Why?
| | Neoplasms | 1 | 2011 | 2666 | 0.030 |
Why?
| | Adolescent | 5 | 2021 | 21555 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2012 | 1185 | 0.030 |
Why?
| | Cell Line, Transformed | 2 | 2006 | 145 | 0.030 |
Why?
| | Electron Transport | 2 | 2006 | 115 | 0.030 |
Why?
| | Acetylation | 1 | 2016 | 254 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 1999 | 316 | 0.030 |
Why?
| | Mitosis | 1 | 2016 | 193 | 0.030 |
Why?
| | Cell Culture Techniques | 1 | 2017 | 363 | 0.030 |
Why?
| | Drug Synergism | 1 | 2016 | 379 | 0.030 |
Why?
| | HeLa Cells | 1 | 2016 | 640 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 690 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2023 | 1999 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2020 | 2182 | 0.030 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2016 | 211 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 892 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2006 | 285 | 0.030 |
Why?
| | Glutathione | 2 | 2006 | 358 | 0.030 |
Why?
| | Glucose | 2 | 2012 | 1018 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2016 | 446 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2016 | 659 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 812 | 0.030 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2012 | 141 | 0.020 |
Why?
| | Colony-Forming Units Assay | 1 | 2012 | 91 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 219 | 0.020 |
Why?
| | Young Adult | 2 | 2021 | 13243 | 0.020 |
Why?
| | Luciferases | 1 | 2012 | 151 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2012 | 116 | 0.020 |
Why?
| | Gene Knockout Techniques | 1 | 2012 | 116 | 0.020 |
Why?
| | Colorado | 1 | 2022 | 4521 | 0.020 |
Why?
| | Cell Line | 2 | 2008 | 2852 | 0.020 |
Why?
| | Genome, Human | 1 | 2014 | 424 | 0.020 |
Why?
| | Embryo, Mammalian | 1 | 2012 | 232 | 0.020 |
Why?
| | Antioxidants | 2 | 2005 | 577 | 0.020 |
Why?
| | Tubulin | 1 | 2012 | 141 | 0.020 |
Why?
| | Extracellular Space | 1 | 2011 | 121 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2012 | 182 | 0.020 |
Why?
| | Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2011 | 21 | 0.020 |
Why?
| | Gene Expression | 1 | 2016 | 1505 | 0.020 |
Why?
| | Adenosine | 1 | 2012 | 227 | 0.020 |
Why?
| | Mammals | 1 | 2012 | 286 | 0.020 |
Why?
| | Gene Silencing | 1 | 2011 | 195 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2011 | 322 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2011 | 845 | 0.020 |
Why?
| | Spin Labels | 1 | 2009 | 48 | 0.020 |
Why?
| | Cattle | 1 | 2011 | 982 | 0.020 |
Why?
| | Pyridines | 1 | 2012 | 508 | 0.020 |
Why?
| | Micronuclei, Chromosome-Defective | 1 | 2008 | 7 | 0.020 |
Why?
| | Genomics | 1 | 2014 | 793 | 0.020 |
Why?
| | Photochemistry | 1 | 2009 | 135 | 0.020 |
Why?
| | Cyclin B1 | 1 | 2008 | 6 | 0.020 |
Why?
| | Cyclin B | 1 | 2008 | 15 | 0.020 |
Why?
| | Immunoblotting | 1 | 2008 | 307 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2014 | 920 | 0.020 |
Why?
| | Dicarbethoxydihydrocollidine | 1 | 2007 | 1 | 0.020 |
Why?
| | Rats | 1 | 2016 | 5676 | 0.020 |
Why?
| | G1 Phase | 1 | 2007 | 71 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1695 | 0.020 |
Why?
| | NIH 3T3 Cells | 1 | 2007 | 144 | 0.020 |
Why?
| | Uncoupling Agents | 1 | 2006 | 2 | 0.020 |
Why?
| | Models, Molecular | 1 | 2012 | 1586 | 0.020 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 2006 | 32 | 0.020 |
Why?
| | Glutathione Disulfide | 1 | 2006 | 33 | 0.020 |
Why?
| | Bromodeoxyuridine | 1 | 2006 | 80 | 0.020 |
Why?
| | Adenoviruses, Human | 1 | 2005 | 27 | 0.020 |
Why?
| | Ceramides | 1 | 2006 | 118 | 0.020 |
Why?
| | Pulmonary Artery | 1 | 2011 | 1083 | 0.020 |
Why?
| | Chronic Disease | 1 | 2011 | 1790 | 0.010 |
Why?
| | RNA | 1 | 2012 | 924 | 0.010 |
Why?
| | Antimycin A | 1 | 2004 | 14 | 0.010 |
Why?
| | Rotenone | 1 | 2004 | 11 | 0.010 |
Why?
| | Glutathione Reductase | 1 | 2004 | 25 | 0.010 |
Why?
| | NADP | 1 | 2004 | 50 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2012 | 3546 | 0.010 |
Why?
| | Manganese | 1 | 2004 | 63 | 0.010 |
Why?
| | Electrons | 1 | 2004 | 86 | 0.010 |
Why?
| | Amitrole | 1 | 2004 | 9 | 0.010 |
Why?
| | Thiazoles | 1 | 2004 | 123 | 0.010 |
Why?
| | Oxidants | 1 | 2004 | 110 | 0.010 |
Why?
| | Osteosarcoma | 1 | 2004 | 75 | 0.010 |
Why?
| | Methacrylates | 1 | 2004 | 116 | 0.010 |
Why?
| | Asbestos | 1 | 2004 | 37 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2006 | 1357 | 0.010 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2004 | 283 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2004 | 316 | 0.010 |
Why?
| | Adenosine Triphosphate | 1 | 2004 | 487 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4295 | 0.010 |
Why?
| | Monocytes | 1 | 2004 | 568 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2002 | 816 | 0.010 |
Why?
| | Unconsciousness | 1 | 1999 | 19 | 0.010 |
Why?
| | Lung Compliance | 1 | 1999 | 49 | 0.010 |
Why?
| | Lung Diseases, Obstructive | 1 | 1999 | 50 | 0.010 |
Why?
| | Tidal Volume | 1 | 1999 | 86 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2004 | 1242 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 2005 | 937 | 0.010 |
Why?
| | Positive-Pressure Respiration | 1 | 1999 | 80 | 0.010 |
Why?
| | Adult | 2 | 2016 | 37821 | 0.010 |
Why?
| | Models, Biological | 1 | 2004 | 1775 | 0.010 |
Why?
| | Nitric Oxide | 1 | 2002 | 914 | 0.010 |
Why?
| | Intubation, Intratracheal | 1 | 1999 | 259 | 0.010 |
Why?
| | Middle Aged | 1 | 2016 | 33355 | 0.010 |
Why?
| | Lung Diseases, Interstitial | 1 | 1999 | 634 | 0.010 |
Why?
| | Lung | 1 | 2004 | 4066 | 0.010 |
Why?
| | Infant, Newborn | 1 | 1999 | 6059 | 0.000 |
Why?
| | Infant | 1 | 1999 | 9467 | 0.000 |
Why?
|
|
Venkataraman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|